Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
We report a case of mesangial proliferative glomerulonephritis with interstitial nephritis associated with multicentric Castleman's disease (MCD) successfully treated with an anti-interleukin-6 receptor antibody (tocilizumab). This mesangial proliferative glomerulonephritis with interstitial nephritis was resistant to methylprednisolone treatment; however, it was markedly improved with tocilizumab, which was administered intravenously at a dose of 8 mg/kg every 2 weeks. These results suggest that tocilizumab is effective for the treatment of mesangial proliferative glomerulonephritis with interstitial nephritis associated with MCD.
Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan.
Naoko
N
Otani
Yoshiyuki
Y
Morishita
Iekuni
I
Oh
Osamu
O
Saito
Fumi
F
Takemoto
Shigeaki
S
Muto
Eiji
E
Kusano
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005871:Castleman Disease / Q000150:complications* / Q000628:therapy*; D015432:Glomerulonephritis, Membranoproliferative / Q000209:etiology* / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009395:Nephritis, Interstitial / Q000209:etiology* / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; C508600:IL6 protein, human; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; C502936:tocilizumab; D008775:Methylprednisolone